PPARA and Alzheimer disease: BACE1 inhibitors, anti‐Aβ antibodies, and other approaches (receptor for advanced glycation end products (RAGE), PPAR, 5‐hydroxytryptamine‐6 (5‐HT6)), most drugs tested in phase III clinical trials for AD failed.